Apollomics

Apollomics EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Apollomics (APLM) as of Oct 17, 2026 is -1.85. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -0.45 — a change of 308.35% (lower).

EV/OCF

-1.85

YoY

308.35%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Apollomics is 2025 -1.85 . EV/OCF (Enterprise Value to Operating Cash Flow) of Apollomics was 2024 -0.45 . It decreases by 308.35% lower compared to the previous year.

The Apollomics EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
-3.81 USD
Jan 1, 2020
-4.40 USD
Jan 1, 2021
-5.84 USD
Jan 1, 2022
0.74 USD
Jan 1, 2023
0.26 USD
Jan 1, 2024
-0.45 USD
Jan 1, 2025
-1.85 USD
The Apollomics EV/OCF history
YEAREV/OCFYoY
-1.85+308.35%
-0.45-273.10%
0.26-64.70%
0.74-112.72%
-5.84+32.63%
-4.40+15.38%
-3.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apollomics Stock analysis

What does Apollomics do? Apollomics Inc is a clinical-stage biotechnology company based in Foster City, California, operating within the Health Care sector. The company went public via an IPO on November 26, 2021, and is listed under the ticker APLM with ISIN KYG0411D1236. Apollomics focuses on the discovery and development of oncology therapies designed to address unmet medical needs. The company's pipeline includes approximately nine drug candidates, six of which are in clinical development. Its lead program involves vebreltinib (APL-101), a c-Met inhibitor being evaluated in a Phase II multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. Another key candidate is uproleselan (APL-106), an E-Selectin antagonist under development as an adjunct to standard chemotherapy for acute myeloid leukemia and other hematologic cancers. Apollomics aims to create therapies that can be combined with existing treatments to enhance immune system engagement and target specific molecular pathways in cancer. The company's website is www.apollomicsinc.com. Apollomics is engaged in advancing innovative oncology treatments through clinical research and development. Apollomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apollomics stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Apollomics is -1.85 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Apollomics changed from -0.45 to -1.85, representing a 308.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Apollomics since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Apollomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Apollomics

All Key Metrics — Apollomics